ROCHE HOLDING AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 220.2 CHF | -0.88% |
|
+0.27% | -9.78% |
| 02:21pm | Scholz pledges further support for the pharmaceutical industry | DP |
| 01:40pm | ROCHE HOLDINGS AG : UBS remains Neutral | ZD |
| Sales 2024 * | 59.97B 65.65B | Sales 2025 * | 63.83B 69.87B | Capitalization | 179B 196B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.32B 14.58B | Net income 2025 * | 14.75B 16.14B | EV / Sales 2024 * | 3.22 x |
| Net Debt 2024 * | 13.91B 15.22B | Net Debt 2025 * | 7.76B 8.5B | EV / Sales 2025 * | 2.93 x |
| P/E ratio 2024 * |
13.1
x | P/E ratio 2025 * |
11.9
x | Employees | 103,605 |
| Yield 2024 * |
4.38% | Yield 2025 * |
4.53% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More press releases
More news
| 1 day | -0.92% | ||
| 1 week | +0.27% | ||
| Current month | -3.96% | ||
| 1 month | -2.17% | ||
| 3 months | -8.84% | ||
| 6 months | -7.14% | ||
| Current year | -9.78% |
1 week
218.50
230.50
1 month
217.00231.50
Current year
217.00255.90
1 year
217.00293.55
3 years
217.00404.20
5 years
217.00404.20
10 years
206.35404.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 65 | 95-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.03% | 121 M€ | -.--% | - | |
| 8.46% | 18 M€ | +3.04% | - | |
| 4.67% | 2 M€ | -.--% | ||
| 2.85% | 6 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 220.6 | -0.72% | 623 633 |
| 24-04-24 | 222.2 | -3.27% | 2,211,530 |
| 24-04-23 | 229.7 | +1.73% | 2,208,142 |
| 24-04-22 | 225.8 | +1.67% | 1,837,156 |
| 24-04-19 | 222.1 | +0.95% | 1,363,531 |
Delayed Quote Swiss Exchange, April 25, 2024 at 08:27 am EDT
More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
222.2
CHF
Average target price
281.1
CHF
Spread / Average Target
+26.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.78% | 196B | |
| +25.61% | 660B | |
| +23.03% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +12.45% | 219B | |
| +6.61% | 199B | |
| -8.75% | 149B | |
| -5.21% | 146B |
- Stock Market
- Equities
- ROG Stock
